From the Journals

Quicker fertility rebound in young women with breast cancer


 

Higher pregnancy rates

Almost 18% of women in the experimental arm reported trying to conceive, and 9.6% of them did so. About 10% of women in the cyclophosphamide arm tried to conceive, and 2.7% did so (P = .03).

The median interval between randomization and pregnancy was 42 months.

For all of the women who became pregnant, endocrine therapy was interrupted. “Women who temporarily interrupt endocrine therapy due to pregnancy should be reminded to resume endocrine therapy following attempted or successful pregnancy,” the investigators wrote.

The patients were taking tamoxifen at least 5 years after receiving chemotherapy, most often as monotherapy. About 5% of the patients underwent up-front ovarian suppression with an aromatase inhibitor, which is a current standard option.

The study was supported by the National Natural Science Foundation of China and other organizations. The investigators and Dr. Partridge disclosed no relevant financial relationships. Dr. Lambertini has consulted for and/or has received speakers fees from Roche, AstraZeneca, Lilly, Novartis, and other companies.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Advanced breast cancer: Palbociclib+ET associated with low burden of cutaneous toxicities
MDedge Hematology and Oncology
Breast MRI less accurate in predicting nodal status after neoadjuvant therapy in invasive lobular carcinoma
MDedge Hematology and Oncology
Link between reproductive factors and breast cancer incidence
MDedge Hematology and Oncology
Risk of 5-year local recurrence declines with event-free years in newly diagnosed breast cancer
MDedge Hematology and Oncology
HER2+ BC: Recurrence risk remains even after achieving pCR with neoadjuvant pertuzumab+trastuzumab
MDedge Hematology and Oncology
Clinical Edge Journal Scan Commentary: Breast Cancer April 2021
MDedge Hematology and Oncology
Cancer screening stopped by pandemic: Repercussions to come?
MDedge Hematology and Oncology
Steroid-refractory pneumonitis from ICIs: Experience at major centers
MDedge Hematology and Oncology
Rankings of most common cancers to shift over next 20 years
MDedge Hematology and Oncology
Personalized cancer vaccine shows early promise across tumor types
MDedge Hematology and Oncology